Investors

Investors

Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

NASDAQ: TTPH
$ 5.78 +0.04 (0.70%)
Day High: 5.81
Day Low:  5.66
Volume:    154,955
11:53 AM ET
Aug 18, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations